Antisense Therapeutics Ltd represents a commitment to developing innovative therapeutics using antisense technology. The company focuses on addressing unmet medical needs in areas like oncology and rare diseases. With a vision to improve patients' quality of life, Antisense Therapeutics Ltd conducts rigorous research and development to advance their pipeline of drug candidates. By leveraging antisense technology, the company aims to target disease-causing genes at the molecular level. Antisense Therapeutics Ltd is dedicated to fostering collaborations, conducting clinical trials, and seeking regulatory approvals to bring potentially life-changing treatments to patients worldwide.

Antisense Therapeutics Ltd primarily operates in Australia and has a presence in several regions globally. The company is focused on developing and commercializing antisense pharmaceuticals for the treatment of various diseases. In Australia, Antisense Therapeutics Ltd is headquartered in Melbourne and operates research and development facilities. The company also collaborates with international partners and conducts clinical trials in different countries, including the United States and Europe. With a global reach, Antisense Therapeutics Ltd aims to bring innovative therapies to patients worldwide.

Antisense Therapeutics Ltd has achieved significant milestones in its journey. The company successfully completed multiple clinical trials, demonstrating the efficacy of its antisense technology in treating various medical conditions. It received regulatory approvals for its drug candidate, ATL1102, for the treatment of Duchenne Muscular Dystrophy (DMD). Furthermore, Antisense Therapeutics secured licensing agreements, allowing the company to expand its reach globally. Antisense Therapeutics Ltd continues to focus on developing innovative therapies and collaborating with key partners to address unmet medical needs, solidifying its position as a leader in the field of antisense therapeutics.

Antisense Therapeutics Ltd is an Australian biopharmaceutical company. Established in 1996, the company focuses on developing and commercializing antisense pharmaceuticals for the treatment of diseases. Antisense Therapeutics Ltd primarily uses RNA-targeted therapeutics to regulate the expression of specific genes involved in various medical conditions. With a strong research and development team, the company has made significant advancements in the field of antisense technology. Antisense Therapeutics Ltd has collaborated with renowned academic institutes and biotechnology companies to further enhance its drug discovery programs. By harnessing the potential of antisense molecules, the company strives to provide innovative treatments for unmet medical needs.

The main competitors of Antisense Therapeutics Ltd in the market include other biotechnology companies focusing on gene therapy and antisense technologies. Some prominent competitors of Antisense Therapeutics Ltd are Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., and Alnylam Pharmaceuticals Inc. These companies also develop innovative therapeutics and treatments using similar technology platforms. However, Antisense Therapeutics Ltd differentiates itself through its unique drug pipeline and focuses on specific disease indications. Despite competition, Antisense Therapeutics Ltd strives to establish itself as a leading player in the field of antisense therapeutics by continuously advancing its research and development efforts.

Antisense Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries. Their focus is on developing novel antisense therapeutics to treat serious diseases, including cancer and rare genetic disorders. As a leading biotech company, Antisense Therapeutics Ltd combines cutting-edge research and development with strategic partnerships to advance innovative drug therapies. With a strong commitment to improving patients' lives, Antisense Therapeutics Ltd plays a significant role in the healthcare sector by leveraging groundbreaking technologies and scientific expertise.

The business model of Antisense Therapeutics Ltd is focused on the development and commercialization of antisense drugs for the treatment of diseases. Antisense Therapeutics Ltd utilizes antisense technology to target specific genes or proteins involved in diseases, aiming to modify their expression or activity. By leveraging this technology, the company seeks to address unmet medical needs across various therapeutic areas, including rare diseases and hormone-related conditions. Antisense Therapeutics Ltd strives to advance its drug candidates through clinical trials and collaborations with pharmaceutical partners, ultimately aiming to provide innovative treatments that improve patient outcomes.

Antisense Therapeutics KGV ir -2,78.

Antisense Therapeutics KUV ir 21,88.

AlleAktien kvalitātes vērtējums Antisense Therapeutics ir 6/10.

gaidāmā Antisense Therapeutics apgrozījums ir 2,66 milj. AUD.

gaidāmā Antisense Therapeutics peļņa ir -20,94 milj. AUD.

Antisense Therapeutics Ltd is a company specializing in the development of innovative therapies for serious diseases. It is based in Melbourne, Australia, and is listed on the Australian Securities Exchange. Antisense Therapeutics' business model involves researching, developing, and marketing antisense therapies. These therapies are based on blocking antisense technology, which allows for the targeted deactivation of specific mRNA molecules. This can regulate the expression of certain proteins in the body, which in turn can help treat or prevent serious diseases. The company has various divisions focused on developing therapies for different indications. One of its key divisions is the development of therapies for use in Myotonic Dystrophy Type 1 (DM1) and Acromegaly. The antisense therapy for DM1 targets an inherited condition caused by an abnormal expansion of CTG trinucleotide repeats in the DMPK gene. There are no approved treatments for this condition. Antisense Therapeutics has developed an antisense therapy called ATL1103, which can block the abnormal CTG trinucleotide repeat and prevent the production of harmful protein molecules. ATL1103 is a potential blockbuster drug with a market potential of $1 billion. The antisense therapy for Acromegaly addresses a condition caused by overactive growth hormone. Currently available therapies have many side effects and are not always effective. Antisense Therapeutics has developed an antisense therapy called ATL1102, which blocks the production of growth hormones and treats the symptoms of Acromegaly. ATL1102 is currently in Phase II of clinical trials. For Multiple Sclerosis (MS), a chronic inflammatory disease of the central nervous system with no cure, Antisense Therapeutics is developing an antisense therapy called ATL1101. It aims to reduce the production of interferon-gamma, a key cause of the inflammation associated with MS. ATL1101 has the potential to be an effective and well-tolerated treatment option for MS patients. Antisense Therapeutics is also exploring the application of antisense therapies in treating cardiovascular diseases such as hyperlipidemia and atherosclerosis. The ATL1102 antisense therapy, in theory, would be able to reduce the risk of cardiovascular complications. The company collaborates with other biotechnology and pharmaceutical companies, offering partnerships in the development and marketing of antisense therapies. These partnerships enable Antisense Therapeutics to accelerate the development of new therapies while minimizing risk. In summary, Antisense Therapeutics is an innovative biotechnology company specializing in the development of antisense therapies. It has various divisions focused on developing therapies for different indications. The antisense therapies developed by Antisense Therapeutics have the potential to improve the lives of millions of patients worldwide. The company works closely with other companies to expedite its research and maximize the success of antisense therapies.

Antisense Therapeutics izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Antisense Therapeutics vai uzņēmums nedod dividendes.

Antisense Therapeutics ISIN ir AU000000ANP4.

Antisense Therapeutics WKN ir 982306.

Antisense Therapeutics simbols ir ANP.AX.

Pēdējo 12 mēnešu laikā Antisense Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Antisense Therapeutics plāno maksāt dividendes 0 AUD apmērā.

Antisense Therapeutics pašreizējā dividendu rentabilitāte ir .

Antisense Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Antisense Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Antisense Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Antisense Therapeutics apmērā 0 AUD, kas tika izmaksāta 26.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.09.2024..

Pēdējās dividendes izmaksa notika 26.09.2024..

Gadā 2023, Antisense Therapeutics izmaksāja 0 AUD dividendes.

Antisense Therapeutics dividendes tiek izmaksātas AUD.